Insulin Device Maker Settles Shareholder Derivative Suit
Insulet Corp. shareholders have agreed to take an undisclosed settlement that includes $425,000 for attorneys in exchange for dropping allegations that executives at the insulin pump manufacturer manipulated sales numbers, the investors told...To view the full article, register now.
Already a subscriber? Click here to view full article